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Patients with adenocarcinoma and non-smoking had better 
survival in chemotherapy of gemcitabine plus oral UFT for 
advanced non-small-cell-lung cancer previously treated with 
platinum
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Background: An open-label single-arm clinical study was conducted 
to evaluate the efﬁcacy and toxicity of combination of gemcitabine and 
UFT in patients with advanced non-small-cell-lung cancer (NSCLC) 
after failure of previous platinum-containing regimens. 
Methods: Patients with advanced NSCLC received an oral administra-
tion of UFT (tegafur 400 mg/m2/day) from days 1 to 14 and intravenous 
injection of gemcitabine 900 mg/m2 on days 8 and 15. This treatment 
was repeated every 3 or 4 weeks. 
Results: A total of 40 patients were enrolled into this study. Eleven 
patients (28%; 95%CI: 14-41%) achieved a partial response. The 
median progression-free survival, median overall survival and 1-year 
survival rate were 121 days, 383 days and 50%, respectively. The most 
common grade 3-4 toxicity was neutropenia (38%) while the frequency 
of grade 3-4 non-hematologic toxicities remained at less than 5%. This 
combination chemotherapy demonstrated a promising effectiveness 
and acceptable toxicity proﬁle for platinum-resistant NSCLC patients. 
A multivariate Cox regression analysis exhibited that adenocarcinoma 
and non-smoking habit as well as good performance status predict bet-
ter survival outcome. 
Conclusions: These factors could potentially bring in serious im-
pact into results of clinical studies for second-line chemotherapy of 
advanced NSCLC. 
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A bi-weekly administration of gemcitabine and docetaxel in 
patients with non-small cell lung cancer
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Background: Combination of gemcitabine and docetaxel (GEM/DOC) 
has shown a favorable activity with its response rate of 34-37.5%, simi-
lar to that of cisplatin and docetaxel in chemotherapy-naïve patients 
with stage IIIb or IV non-small cell lung cancer (NSCLC). However, 
neutropenia and pulmonary toxicities were related to the combination 
chemotherapy. Especially relatively high rate of pulmonary toxicities 
have been identiﬁed in monthly or weekly administration setting of 
both combination.
Purpose: We evaluated the feasibility and efﬁcacy of biweekly GEM/
DOC chemotherapy in patients with NSCLC.
Patients and Methods: Forty-four patients with post-operative recur-
rences and eighteen patients with unresectable advanced non-small cell 
lung cancer were enrolled in this study.
Those patients received 1000mg/m2 of GEM and 30mg/m2 of DOC 
bi-weekly, q=2 weeks. Response rate, toxicities, and completion rate 
are evaluated after 4 cycles. Those patients were basically treated on 
outpatient basis.
Results: A total of 62 patiets were treated with combination of GEM/
DOC. 
Patients characteristics were as follows; recurrent/unresectable: 44/18; 
male/female: 38/24; median age: 66.1 (range 32-80); perfomance status 
0/1/2: 41/19/2; adeno/squamous/large: 45/15/2; chemo naïve/previ-
ously treated: 24/38.
A response rate was 20.7%(CR 3, PR 9, SD 34, PD 12, and NE 4). 
Response rates by tumor pathological type were 25% (11/44) with 
adenocarcinoma and 8.3% (1/12) with squamous cell carcinoma. Over 
grade 3 leucopenia was occurred in 17.7% (11/62), neutropenia in 
32.3% (20/62), skin toxicities in 3.2% (2/62), and pulmonary toxici-
ties in 3.2% (2/62). Treatment completion rate was 93.5%(58/62). The 
reasons of treatment discontinuation were pneumonia, skin rush, and 
angiodynia.
Conclusion: GEM/ DOC regimen is a feasible and efﬁcacious regimen 
against advanced and/or recurrent NSCLC. Biweekly administration of 
GEM/DOC may decrease hematological toxicities and be well-toler-
ated regimen. In addition, the rate of pulmonary toxicities in biweekly 
GEM/DOC may be less compared with other scheduled combination.
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Prospective phase II trial of a combination of gemcitabine, 
cisplatin and UFT as first-line treatment in patients with advanced, 
unresectable, non-small cell lung carcinoma
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Backgroud: Most patients with advanced non-small cell lung cancer 
(NSCLC) receive either single agents or doublet chemotherapy. For 
non-elderly pts in good performance status, platinum-based double 
combinations represent the standard treatment. Meta-analysis have 
showed combination chemotherapy consisting of cisplatin plus new 
agent yielded a substantial survival advantage compared with carbo-
platin plus new agent in patients with advanced NSCLC. And oral UFT 
had the survival advantage in adjuvant setting. Gemcitabine may be 
more effective in form of ﬁxed dose rate infusion (FDRI, 10 mg/kg/
min) than conventional infusion schedule. Therefore we performed a 
phase II study using the combination of gemcitabine, cisplatin and UFT 
as a ﬁrst line therapy in patients with advanced NSCLC.
Methods: Eligible patients had histologically or cytologically con-
ﬁrmed stage IIIB or IV NSCLC with good performance status and were 
chemotherapy-naive. This study was two-stage design and planned 
number of patients was forty-seven. Gemcitabine (1,250mg/m2, 10mg/
kg/min on days 1 and 8) and cisplatin (75mg/§⁄ on day 1) were injected 
intravenously and UFT (400mg/day) was administered orally on day 1-
